VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Caudle on Upcoming Breast Cancer Trial Results

Abigail S. Caudle, MD
Published: Wednesday, Apr 24, 2013

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Caudle first highlights the ACOSOG Z1071 trial, which aimed to analyze the false-negative rate of a sentinel lymph node dissection after neoadjuvant chemotherapy. This trial closed early with higher than expected accrual, demonstrating physicians' interest.

Further, Caudle is excited to see how the results of the SWOG RxPONDER trial could benefit patients. This trial is evaluating the effect of chemotherapy in patients with breast cancer who have a low to intermediate recurrence score.
Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Caudle first highlights the ACOSOG Z1071 trial, which aimed to analyze the false-negative rate of a sentinel lymph node dissection after neoadjuvant chemotherapy. This trial closed early with higher than expected accrual, demonstrating physicians' interest.

Further, Caudle is excited to see how the results of the SWOG RxPONDER trial could benefit patients. This trial is evaluating the effect of chemotherapy in patients with breast cancer who have a low to intermediate recurrence score.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x